## **PCT**

(22) International Filing Date:

# WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(30) Priority Data:
9524938.9
6 December 1995 (06.12.95)
GB

4 December 1996 (04.12.96)

(71) Applicant (for all designated States except US): ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London WIY 6LN (GB)

(72) Inventors; and

(75) Inventors/Applicants (for US only): KEELING, Peter, Lewis [GB/US]; ExSeed Genetics, Iowa State University, 1573 Food Science Building, Ames, IA 50011-1061 (US). KNIGHT, Mary, Elizabeth [GB/GB]; 14 Greenfinch Close, Heathlands Park, Crowthorne, Berkshire RG11 6TZ (GB).

(74) Agents: HUSKISSON, Frank, Mackie et al.; Zeneca Agrochemicals, Intellectual Property Dept., Jealon's Hill Research Station, P.O. Box 3538, Bracknell, Berkshire RG42 6YA (GB). BI) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

#### Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

With an indication in relation to a deposited microorganism furnished under Rule 13bis separately from the description.

Date of receipt by the International Bureau:

27 December 1996 (27.12.96)

(54) Title: MODIFICATION OF STARCH SYNTHESIS IN PLANTS

#### (57) Abstract

Plants, particularly cereal plants which have modifications to their starch synthesising pathway contain a DNA specifying the enzyme soluble starch synthase which has the sequence SEQ ID NO 1 or SEQ ID NO 2 or SEQ ID NO 3. The inserted gene may be inserted in a sense or anti-sense construct. The alteration introduced by the inserted genes may be a greater or reduced ability to produce starch or starch which has a different fine structure such as a different pattern of branching.

## FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Amenia	GB	United Kingdom	MW	Malawi
AT	Austria	GR	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Rarbados	GR	Greece	NL	Nesherlanda
BE		HU	Hungary	NO	Norway
BF	Belgium	18	treland	NZ.	New Zealand
	Burkina Puro			PL.	Poland
BG	Bulgaria	IT	Italy		
r)	Benin	3P	Japan	PT	Portugal
BR	Brizit	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgystan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic	SD	Sudan
CF	Central African Republic		of Korea	SE	Sweden
CG	Congo	KR	Republic of Kores	SG	Singapore
CH	Switzerland	KZ.	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LR	Liberia	SZ.	Swaziland
CS	Czechoelovakia	LT	Lithuanis	TD	Chad
CZ	Czech Republic	LU	Luxembourg	TG	Togo
DE	Germany	LV	Latvia	TJ	Tajikistan
DK	Denmark	MC	Monaco	TT	Trinided and Tobago
EE	Estonia	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	UG	Ugande
FI	Finland	ML	Mali	US	United States of America
FR	Prance	MN	Mongolia	UZ	Uzbekistan
GA	Gabon	MR	Mauritania	VN	Viet Nam

· I -

#### MODIFICATION OF STARCH SYNTHESIS IN PLANTS

This invention relates to the alteration of the biosynthetic pathway which leads to production of starch in plants. By the term "alteration" we mean a change from normal of the amount or quality of the starch which the plant produces. More particularly, the invention relates to the isolation, purification and characterisation of the DNAs encoding several forms of the enzyme soluble starch synthase and the use of those DNAs through genetic modification of the plant genome to alter the starch production.

The invention also relates to novel plants having an improved ability to produce starch including an improved ability to produce structurally-altered starch.

Our previous studies have led to a new understanding of the metabolic pathway of starch synthesis in developing starch storing tissues (Keeling et al, 1988, Plant Physiology, 87:311-319; Keeling, 1989, ed. C.D. Boyer, J.C. Shannon and R.C. Harrison; pp.63-78, being a presentation at the 4th Annual Penn State Symposium in Plant Physiology).

Starch is an important end-product of carbon fixation during photosynthesis in leaves and is an important storage product in seeds and fruits. In economic terms, the starch produced by the edible portions of three grain crops, wheat, rice and maize, provide approximately two-thirds of the world's food calculated as calories.

Starch is synthesised in the plastid compartment, the chloroplast, in photosynthetic cells or the amyloplast in non-photosynthetic cells. The biochemical pathway of starch biosynthesis in leaves has been well-characterised (Figure 1). In contrast, little is known of the pathway of starch biosynthesis in storage organs.

Two principal methods for the control of gene expression are known.

These are referred to in the art as "antisense downregulation" and "sense downregulation" or "cosuppression". Both of these methods lead to an inhibition of expression of the target gene. Overexpression is achieved by insertion of one or more than one extra copies of the selected gene. Other lesser used methods

10

15

20

25

10

15

20

involve modification of the genetic control elements, the promoter and control sequences, to achieve greater or lesser expression of an inserted gene.

In antisense downregulation, a DNA which is complementary to all or part of the target gene is inserted into the genome in reverse orientation and without its translation initiation signal. The simplest theory is that such an antisense gene, which is transcribable but not translatable, produces mRNA which is complementary in sequence to mRNA product transcribed from the endogenous gene: that antisense mRNA then binds with the naturally produced "sense" mRNA to form a duplex which inhibits translation of the natural mRNA to protein. It is not necessary that the inserted antisense gene be equal in length to the endogenous gene sequence: a fragment is sufficient. The size of the fragment does not appear to be particularly important. Fragments as small as 40 or so nucleotides have been reported to be effective. Generally somewhere in the region of 50 nucleotides is accepted as sufficient to obtain the inhibitory effect. However, it has to be said that fewer nucleotides may very well work: a greater number, up to the equivalent of full length, will certainly work. It is usual simply to use a fragment length for which there is a convenient restriction enzyme cleavage site somewhere downstream of fifty nucleotides. The fact that only a fragment of the gene is required means that not all of the gene need be sequenced. It also means that commonly a cDNA will suffice, obviating the need to isolate the full genomic sequence.

The antisense fragment does not have to be precisely the same as the endogenous complementary strand of the target gene. There simply has to be sufficient sequence similarity to achieve inhibition of the target gene. This is an important feature of antisense technology as it permits the use of a sequence which has been derived from one plant species to be effective in another and obviates the need to construct antisense vectors for each individual species of interest.

Although sequences isolated from one species may be effective in another, it is not infrequent to find exceptions where the degree of sequence similarity between one species and the other is insufficient for the effect to be obtained. In such cases, it may be necessary to isolate the species-specific homologue.

30

Antisense downregulation technology is well-established in the art. It is the subject of several textbooks and many hundreds of journal publications. The principal patent reference is European Patent No. 240,208 in the name of Calgene Inc. There is no reason to doubt the operability of antisense technology. It is well-established, used routinely in laboratories around the world and products in which it has been used are on the market.

Both overexpression and downregulation are achieved by "sense" technology. If a full length copy of the target gene is inserted into the genome then a range of phenotypes is obtained, some overexpressing the target gene, some underexpressing. A population of plants produces by this method may then be screened and individual phenotypes isolated. As with antisense, the inserted sequence is lacking in a translation initiation signal. Another similarity with antisense is that the inserted sequence need not be a full length copy. Indeed, it has been found that the distribution of over- and under- expressing phenotypes is skewed in favour of underexpression and this is advantageous when gene inhibition is the desired effect. For overexpression, it is preferable that the inserted copy gene retain its translation initiation codon. The principal patent reference on cosuppression is European Patent 465,572 in the name of DNA Plant Technology Inc. There is no reason to doubt the operability of this technology. It is well-established, used routinely in laboratories around the world and products in which it has been used are on the market.

Sense and antisense gene regulation is reviewed by Bird and Ray in Biotechnology and Genetic Engineering Reviews 9: 207-227 (1991). The use of these techniques to control selected genes in tomato has been described by Gray et.al., Plant Molecular Biology, 19: 69-87 (1992).

Gene control by any of the methods described requires insertion of the sense or antisense sequence, with appropriate promoters and termination sequences containing polyadenylation signals, into the genome of the target plant species by transformation, followed by regeneration of the transformants into whole plants. It is probably fair to say that transformation methods exist for most plant species or can be obtained by adaptation of available methods.

10

15

20

25

For dicotyledonous plants the most widely used method is Agrobacterium-mediated transformation. This is the best known, most widely studied and, therefore, best understood of all transformation methods. The rhizobacterium Agrobacterium tumefaciens, or the related Agrobacterium rhizogenes, contain certain plasmids which, in nature, cause the formation of disease symptoms, crown gall or hairy root tumours, in plants which are infected by the bacterium. Part of the mechanism employed by Agrobacterium in pathogenesis is that a section of plasmid DNA which is bounded by right and left border regions is transferred stably into the genome of the infected plant. Therefore, if foreign DNA is inserted into the so-called "transfer" region (T-region) in substitution for the genes normally present therein, that foreign gene will be transferred into the plant genome. There are many hundreds of references in the journal literature, in textbooks and in patents and the methodology is well-established.

The effectiveness of Agrobacterium is restricted to the host range of the microorganism and is thus restricted more or less to dicotyledonous plant species. In general monocotyledonous species, which include the important cereal crops, are not amenable to transformation by the Agrobacterium method. Various methods for the direct insertion of DNA into the nucleus of monocot cells are known.

In the ballistic method, microparticles of dense material, usually gold or tungsten, are fired at high velocity at the target cells where they penetrate the cells, opening an aperture in the cell wall through which DNA may enter. The DNA may be coated on to the microparticles or may be added to the culture medium.

In microinjection, the DNA is inserted by injection into individual cells via an ultrafine hollow needle.

Another method, applicable to both monocots and dicots, involves creating a suspension of the target cells in a liquid, adding microscopic needle-like material. such as silicon carbide or silicon nitride "whiskers", and agitating so that the cells and whiskers collide and DNA present in the liquid enters the cell.

In summary, then, the requirements for both sense and antisense technology are known and the methods by which the required sequences may be introduced are

15

5

10

20

25

known. What remains, then is to identify genes whose regulation will be expected to have a desired effect, isolate them or isolate a fragment of sufficiently effective length, construct a chimeric gene in which the effective fragment is inserted between promoter and termination signals, and insert the construct into cells of the target plant species by transformation. Whole plants may then be regenerated from the transformed cells.

An object of the present invention is to provide DNAs encoding soluble starch synthases.

An further object of the invention is to provide novel plants having an increased capacity to produce starch and a capacity to produce starch with an altered fine structure.

According to the present invention there is provided cDNAs having the sequences of the inserts in plasmids pSSS6, pSSS10.1 and pSSS6.31 and sequences having sufficient similarity such that when inserted into the genome of an organism which produces starch, the synthesis of starch is altered.

The plasmid pSSS6 was deposited under the terms of the Budapest Treaty, with the National Collections of Industrial and Marine Bacteria Limited, 23 St Machar Drive, Aberdeen AB1 2RY, on 13th June 1994, under the Accession Number 40651.

The plasmids pSSS6.31 and pSSS10.1 were deposited under the terms of the Budapest Treaty, with the National Collections of Industrial and Marine Bacteria Limited, 23 St Machar Drive, Aberdeen AB1 2RY, on 22nd August 1994, under the Accession Numbers NCIMB 40679 and 40680 respectively.

The invention also provides the cDNAs, encoding soluble starch synthases which have the sequences SEQ-ID-NO-1, SEQ-ID-NO-2 AND SEQ-ID-NO-3.

The invention also provides transformed plants containing one or more copies of one or more of the said cDNAs in sense or antisense orientation.

The description which follows will describe a method for the isolation of the genes encoding soluble starch synthases from maize.

These DNAs can be used for the isolation of the corresponding genomic sequences. Either the cDNAs or the genes can then be used in studies leading to the

10

5

15

20

25

10

15

20

increase in starch yield. One possible application could be the use of these sequences to increase gene dosage of SSS in transformed crop plants to determine the contribution of SSS to the net regulation of starch biosynthesis, and to modify the levels of starch synthesised by the plant. The introduction of additional copies of SSS genes should produce greater levels of the enzyme in the amyloplasts. Increased gene expression may also be elicited by introducing multiple copies of enhancer sequences into the 5'-untranscribed region of SSS gene. If the enzyme is rate-limiting to starch biosynthesis, then the rate of starch biosynthesis would be expected to increase in the transformed plants. By virtue of this invention it will also be possible to alter the kinetic properties of the endopserm enzyme through protein engineering. Obviously a number of other parameters could also be improved. The present invention will now be described, by way of illustration, by the following Example and with reference to the accompanying drawings of which:

Figure 1 shows the reactions involved in the biosynthetic pathways of starch and glucose in leaves. The abbreviations used are: G-3-P,glyceraldehyde-3-phosphate; DHAP, dihydroxyacetone phosphate; Pi, orthophosphate; PPi, inorganic pyrophosphate. The reactions are catalysed by the following enzymes:

1) phosphoglycerate kinase/glyceraldehyde-3-phosphate dehydrogenase

2) triose-phosphate isomerase

3) aldolase

- 4) fructose-1,6-bisphosphatase
- 5) hexose phosphate isomerase
- 6) phosphoglucomutase
- 25 7) ADP-glucose pyrophosphorylase
  - 8) starch synthase
  - 9) UDP-glucose pyrophosphorylase
  - 10) sucrose phosphate synthase
  - 11) sucrose phosphatase
- 30 12) orthophosphate/triose phosphate translocator
  - 13) inorganic pyrophosphatase

Figure 2 shows the proposed metabolic pathway of starch biosynthesis in wheat endosperm (Keeling et. al. 1988). The abbreviations used are the same as in Figure 1. The reactions are catalysed by the following enzymes:

5

1)	sucrose	synthase

- UDP-glucose pyrophosphorylase
- 3) hexokinase
- 4) phosphoglucomutase

10

- 5) hexose-phosphate isomerase
- 6) ATP-dependent phosphofructokinase
- 7) PPi-dependent phosphofructokinase
- 8) aldolase
- 9) triose-phosphate isomerase

15

- 10) hexose-phosphate translocator
- 11) ADP-glucose pyrophosphorylase
- 12) starch synthase
- 13) sucrose phosphate synthase
- 14) sucrose phophatase

20

30

# USE OF SOLUBLE STARCH SYNTHASE OR BRANCHING ENZYME

Using standard cloning techniques, the SSS genes may be isolated. The source of the genes was a US yellow-dent corn line of Zea mays, from which the enzyme protein was purified.

Endosperms from the maize line were homogenised in a buffer which maintains the SSS in active form.

Purification of the SSS from maize has been achieved by a combination of ammonium sulphate precipitation, DEAE-cellulose chromatography, gel-filtration, phenyl Superose and FPLC using a Mono-Q column. This results in several hundred-fold purification with yields up to 5%. The SSS polypeptide was a single subunit of molecular weight 76kDa. Other SSS polypeptides were present in a US dent inbred line at around 60kDa, 70kDa and 105kDa molecular weight.

15

20

25

30

Ammonium sulphate precipitation of SSS I is best achieved using 10-35% ammonium sulphate which produces a translucent SSS-enriched pellet which is next dialysed and further fractionated using DEAE-cellulose ion-exchange chromatography (2.5 x 5cm column). SSS was eluted with a 150 ml gradient of KCl (0-0.6M) and fractions collected. These steps increase specific activities by up to 12-fold. The DEAE peak fractions were concentrated by precipitation with ammonium sulphate (40%) and the resulting pellet dissolved in buffer and fractionated on a Sephacryl S-200 column (2.5 x 100 cm) equilibrated with buffer and fractions collected. These steps increase specific activities by up to 8-fold. A Phenyl-Superose column was equilibrated with buffer containing ammonium sulphate. SSSI did not bind and was present in the pass-through fraction. These steps increase specific activities by up to 2-fold. Finally, a Mono-Q column was equilibrated with buffer and charged with the Phenyl-Superose pass-through fraction. The enzymes were eluted from the column using a 12 ml linear gradient of 0-0.5 M KCl and fractions collected. These steps increase specific activities by up to 5-fold.

In the final purification step the SSS preparations were loaded on to SDS PAGE gels. The bands corresponding to the SSS polypeptides were cut out and eluted. The polypeptide was sequenced using standard amino acid sequencing techniques.

In order to produce a pure antigen for antibody production, we decided to use starch granules as our starting-point for isolation of SSS proteins. Kernels were homogenised in buffer by grinding in a Waring blender. The homogenate filtered through miracloth and centrifuged. After discarding the supernatant and the discoloured material that overlays the white starch pellet, the pellet was washed twice with buffer and centrifuged. Starch was washed a final time with chilled acetone and following centrifugation, dried under a stream of air before storing at -20°C. Granule protein was extracted by boiling 1.4 g starch for 10 minutes in 50ml SDS-PAGE sample buffer (2% SDS, 5% 2-mercaptoethanol, 10% glycerol and 62.5 mM Tris/HCl, pH 6.8) which lacked bromophenol blue. After cooling and centrifugation at 25,000 g at 4°C for 15 minutes, the supernatant was mixed with an equal volume of 30% TCA and allowed to stand at 4°C for 1 hour. The solution was centrifuged again and pellet washed twice with 10 ml acetone before resuspension in 1.4 ml SDS-PAGE sample buffer. Following separation of granule-derived proteins by SDS-PAGE, the SSS proteins (eg 60kDa, 76kDa etc) bands were electrochuted and used as antigen (three 50ug doses at 4-week intervals, in New Zealand white rabbits) to generate polyclonal antibodies in a rabbit. The antibodies were then tested for specificity to the SSS

. 5

11

. 10 polypeptides. Antibodies were monospecific and have enabled a thorough analysis of enzyme activities and expression studies.

N-terminal amino acid sequences were also obtained from the polypeptides. These proteins were shown to be identical with soluble proteins on the basis of (i) N-terminal sequences to the SSSs as purified by conventional means and sequenced were identical to the granule derived proteins, and (ii) protease digests gave peptide maps which were also identical.

Amino acid sequencing of the maize SSS polypeptide has yielded the following partial sequences:

N-terminal... CVAELSREGPAPR

Internal sequences:

KNYANAFYTETHI
ELGGYIYGQNDMFVVNNDHASLVPVLLAAKYIR
EVTTAEGGSGLNELL
GKIDNTVVVASEQDSY

The antibodies may be used to screen a maize endosperm cDNA library for clones derived from the mRNAs for SSS in an in vitro transcription/ translation system. Synthetic oligos may be constructed and used to screen maize endosperm cDNA library. The SSS sequence may be compared to the amino acid sequence of pea SSS I and SSS II published by Dry et al (1991, Plant Journal 2:193-202) or rice SSS published by Baba et al (1993, Plant Physiology 103, 565-573). Interestingly, the clone obtained from rice SSS is not correctly identified. The N-terminal sequence AELSREG is stated to be part of the transit peptide sequence of the rice clone. This error must have occurred because of protein isolation problems from rice kernels: presumably a portion of the protein was cleaved prior to isolation. Using our N-terminal sequence, the corrected molecular weight of the rice clone is around 69kDa and not 55 or 57kDa as suggested by Baba et al.

# cDNA LIBRARY SCREENING AND ISOLATION OF SSS cDNA CLONES

RNA was extracted from from 21 DAP endosperm (obtained from the inbred line B73) after removal of pericarp and embryo. The library consisted of ~900,000 recombinant clones. A probe for granule bound starch synthase was generated using PCR and used to screen an aliquot of the library, ~500,000 recombinants. This screening yielded approximately 200 positive signals. Isolation and sequencing of a number showed them to be full length GBSS cDNA clones.

An oligonucleotide was synthesised to N-terminal sequence obtained from the purified SSS protein and used to screen the same aliquot of library as that used for the GBSS screening. No positive signals were obtained. A long oligonucleotide probe was then synthesised to the ADP-ADPG binding region and following sequence, based on a comparison of the sequences published for pea SSS, rice SSS and maize GBSS.

The sequence of the oligonucleotide was GGT/C GGA/G CTA/T GGAGATGTTTGTGGA/T TCACTCCCAATTGCTCTT/G GCTCTTCGTGGA/T CATCGTGTG/T ATGGTTGT.

- Fifteen strong signals were obtained, all were picked, of these ten plaque purified after two rounds of purification. Restriction analysis of all ten showed them to fall into two classes. Sequence analysis showed both classes to be starch synthases.

  Screening of a maize seedling library (Clontech) gave positive signals using 5' probes from one class of clones only.
- A cDNA library from the inbred line W64A was screened and full length clones were isolated as judged by comparison with N-terminal sequence.

## CHARACTERISATION OF cDNA CLONES

The isolated cDNAs were sequenced and are given herewith as SEQ-ID-NO-1, NO-2 and NO-3.

For comparison, the deduced amino acid sequences are shown here with the sequences obtained directly from the protein:
CVAELSREGPAPR

peptide derived

CVAELSREGPAPR deduced cDNA

KXYANAFYTETHI peptide derived

KNYANAFYSEKHI deduced cDNA

35

25

**EVTTAEGGSGLNELL** 

peptide derived

**EVTTAEGGQGLNELL** 

deduced cDNA 10.52

ELGGYIYGANXMFVVNXXHASLVPVLLAAKY

peptide derived

ELGGYIYGQNCMLVVNDWHASLEPVLLAAKY

deduced cDNA 10.52

**GKIDNTVVVASEQDSY** 

peptide derived

**GSIDNTVVVASEQDSE** 

deduced cDNA10.52

10

Isolated from soluble 76kDa protein.....
GLVVTRDRDRIQ-VASNR

peptide derived

GAVVTADRIVTVSKGYS 10.52

deduced cDNA

Clone SSS6.31 contained none of these internal sequences. The motif for the binding-site of ADPG and ADP, thought to be part of the active site of starch synthases is found in all clones near to the 5' end and is followed by the highly conserved sequence on which the oligonucleotide probe was based. The highly conserved domain SRFEPCGLNQLYAMXYGTXXXXXXXGGLRDTV is present in SSS10.52 but is slightly modified in SSS6.31 in that the EPC motif is replaced with an AG motif.

Expression of maize starch synthases in Escherichia coli BL21(DE3).

These SSS clones have been transfected into E.coli. The SSS activity was measured and are reported in the Table below.

Plasmids	Maize	starch	N-terminus	Protein	Specific
	synthase go	enes			-

			(mg/mL)	Activities*
·				(units/mg Protein)
pET21a	Native plasmid	<no insert=""></no>	1.8	.009
pEXS-3a	MSSSII (MSSS631)	GENVMNVIV V	2.8	0.069
pEXS-8	MSSSI (MSSS6-	CVAELSREGP	1.9	0.097
pEXS-9	4)	GSVGAALRSY	1.8	0.515
pEXS-wx	MSSSIII (MSSS5.6)	ASAGMNVVF V	2.0	0.033
	MGBSS (waxy)	·		

 One unit activity is defined as one mmol glucose incorporated into a-1,4 glucan per minute at 25°C using 5 mg/mL glycogen as primer.

#### GENE CONSTRUCTS FOR TRANSFORMATION

The gene constructs require the presence of an amyloplast transit peptide to ensure its correct localisation in the amyloplast. It is believed that chloroplast transit peptides have similar sequences but other potential sources are available such as that attached to ADPG pyrophosphorylase (Plant Mol. Biol. Reporter (1991) 9, 104-126). Other potential transit peptides are those of small subunit RUBISCO, acetolactate synthase, glyceraldehyde-3P-dehydrogenase and nitrite reductase. For example,

Consensus sequence of the transit peptide of small subunit RUBISCO from many genotypes has the sequence:

MASSMLSSAAV%ATRTNPAQAS MVAPF SNGGRVOC

MVAPFTGLKSAAFPVSRK

**QNLDITSIA** 

and the corn small subunit RUBISCO has the sequence:

MAPTVMMASSAT-ATRTNPAQAS SNGGRIRC

AVAPFQGLKSTASLPVARR

SSRSLGNVA

The transit peptide of leaf starch synthase from corn has the sequence:

MA ALATSQLVAT RAGLGVPDAS TFRRGAAQGL RGARASAAAD TLSMRTASARA

20 APRHQQQARR GGRFPSLVVC

The transit peptide of leaf glyceraldehyde-3P- dehydrogenase from corn has the sequence:

MAQILAPS TQWQMRITKT SPCATPITSK MWSSLVMKQT KKVAHSAKFR VMAVNSENGT

The putative transit peptide from ADPG pyrophosphorylase from wheat has the sequence: RASPPSESRA PLRAPQRSAT RQHQARQGPR RMC

It is possible however to express the genes constitutively using one of the well-known constitutive promoters such as CaMV35S but there may be biochemical penalties in the plant resulting from increased starch deposition throughout the entire plant. Deposition in the endosperm is much preferred.

Possible promoters for use in the invention include the promoters of the starch synthase gene, bound starch synthase gene, endopserm hsp70 gene, ADPG pyrophosphorylase gene, and the sucrose synthase gene.

lasmid name	Promoter	Intron	Targetting	Gene
pHKH1	CaMV35S	adh1	WxTrPep	GUS
pSh1PIGN	CaMV35S	adhi	WxTrPep	GUS
pSh2PIGN	CaMV35S	adhl	WxTrPep	GUS

FOR TESTING IN SUSPENSION CELL CULTURES:					
Plasmid name	Promoter	Intron	Targetting	Gene	
p***1	CaMV35S	Shl	WxTrPep	GUS	
p***2	CaMV35S	adhi	WxTrPep	GUS	

Plasmid name	Promoter	Intron	Targetting	Gene
p***21	Waxy	Sh1	WxTrPep	SSS and/or BE
p***22	Waxy	Adh1	WxTrPep	SSS and/or BE
p***23	Shi	Sh1	WxTrPep	SSS and/or BE
p***24	Sh1	Adhl	WxTrPep	SSS and/or BE
p***25°	Sh2	Sh1	WxTrPep	SSS and/or BE
p***26	Sh2	Adhl	WxTrPep	SSS and/or BE
p***27	hsp70	Shl	WxTrPep	SSS and/or BE
p***28	hsp70	Adhi	WxTrPep	SSS and/or BE

#### TRANSFORMATION

(i) Insertion of extra copies of the gene

Maize genomic DNAs isolated as above may subsequently be transformed into either protoplasts or other tissues of a maize inbred line or population. The existing gene promoters ensure that the extra genes are expressed only in the developing endosperm at the correct developmental time. The protein sequences likewise ensure that the enzymes are inserted into the amyloplast.

Transgenic maize plants are regenerated and the endosperms of these plants are tested for increased SSS enzyme activity. The kernels are also tested for enhanced rate of starch synthesis at different temperatures. The plants are then included in a breeding programme to produce new maize hybrids with higher rates of starch synthesis at temperatures above the normal optimum.

(ii) Insertion of genes specifying SSS

15

20

25

5

10

This is also achieved by standard cloning techniques. The source of the temperature-stable forms of the SSS genes is any organism that can make starch or glycogen. Potential donor organisms are screened and identified as described above. Thereafter there are two approaches:

- (a) via enzyme purification and antibody/sequence generation using the protocol described above.
- (b) using SSS cDNAs as heterologous probes to identify the genomic DNAs for SSS in libraries from the organism concerned. The gene transformation, plant regeneration and testing protocols are as described above. In this instance it is necessary to make gene constructs for transformation which contain the regulatory sequences from maize endosperm SSS or another maize endosperm starch synthesis pathway enzyme to ensure expression in endosperm at the correct developmental time (eg, ADPG pyrophosphorylase).

Gene constructs used to transform plants requires the regulatory sequences from maize endosperm SSS or another maize endosperm starch synthesis pathway enzyme to ensure expression in endosperm at the correct development time (eg, ADPG pyrophosphorylase).

Furthermore the gene constructs also requires a suitable amyloplast transit-peptide sequence such as from maize endosperm SSS or another maize endosperm starch synthesis pathway enzyme to censure expression of the amyloplast at the correct developmental time (eg, ADPG pyrophosphorylase).

Genetic protein engineering techniques may also be used to alter the amino acid sequence of the SSS enzymes to impart higher temperature optima for activity. The genes for SSS may be cloned into a bacteria which relies on these enzymes for survival. Selection for bacteria surviving at evaluated temperatures enables the isolation of mutated thermostable enzyme forms. Transformation of maize with the altered genes is carried out as described above.

10

15

5

(iii) Changing the ratios of activities of the isoforms of enzymes SSS

This is also achieved by standard cloning techniques. The source of the SSS genes is maize using the protocol described above. Plants are then transformed by insertion of extra gene copies of the isoforms of SSS enzymes and/or by insertion of anti- sense gene constructs. The gene promoters and other regulatory sequences may also be altered to achieve increased amounts of the enzyme in the recipient plant.

(iv) Insertion of a gene or genes specifying SSS with activities which effect a change in the fine structure of the starch.

20

25

This is also achieved by standard cloning techniques. The source of the special forms of the SSS is any organism that can make starch. Potential donor organisms are screened and identified as described above. Thereafter there are two approaches:

- via enzyme purification and antibody/sequence generation using the protocol described above.
  - (b) using SSS cDNAs as heterologous probes to identify the genomic DNAs for SSS in libraries from the organism concerned. The gene transformation, plant regeneration and testing protocols are as described above. In this instance it is necessary to make gene

constructs for transformation which contain the regulatory sequences from maize endosperm SSS or another maize endosperm starch synthesis pathway enzyme to ensure expression in endosperm at the correct developmental time (eg, ADPG pyrophosphorylase).

#### Full length clone sequences

SEQ-ID-NO1; DNA; 2992 BP.

CC NOTE: ORIGINAL SEQUENCE NAME WAS SSS1052 and SSS64

SQ SEQUENCE 2992 BP; 758 A; 655 C; 801 G; 776 T; 2 OTHER:

GAATTCGCGG CCGCCTTATT TCTGGTTGGC CACATACATC ATCCAAAAAA CTTTATTATT

GAATTACAAC TAATAAGCAA TCTAAAAGAG GGCACCACCA ATGATGTGTT GTTGGTAGGA

GGCCGCTGGG TCTGTCAAAG CAAGTTGGAC AAAGGGCAAC AATTGTTGTA
10 GTTGTAAGAG

GGTTGCGGGG TTAGCCGCAA ACTGCTGGTA GAAAGGCAGC AACTGTTGCT

GGAAGCACGG TTTGCTGCAG CTGTTGTGCC CTGATGGTTT GTACCAATGA

15 GATAGGGCTG GCGATTGTTG AAACAACAAG GGCGATAAAG GTATGTTGCT TGCTGCGATT

GCTTGTTGAA GCCTATATGG TTGAAGAGCT GGGTTTTCAC ATATTGAAGC TATAATTGAT

GGAAGGTATG GGGGAAGAAG GGAAGCTATA GGAGCTTGTG AGCATTGAGG
20 GAAAATTGTC

GCGTTAGCAA CACATGTAGA AAGAGCAAGG AGCATAAGGA GGGAAAATAT

ATTGTTGCGC GCGATCCACG GCCCCCCCC CCCGCGCTCC TGTCTGCTCT

25 AATGGCGACG CCCTCGGCCG TGGGCGCCGC GTGCCTCCTC CTCGCGCGGG
NCG CCTGGCC

GGCCGCCGTC GGCGACCGGG CGCGCCCGCG GAGGCTCCAG CGCGTGCTGC GCCGCCGGTG

CGTCGCGGAG CTGAGCAGGG AGGGGCCCGC GCCGCGCCCG CTGCCACCCG

5 GACGCCGCCG CCCGTGCCCG ACGCCGGCCT GGGGGACCTC GGTCTCGAAC CTGAAGGGAT

TGCTGAAGGT TCCATCGATA ACACAGTAGT TGTGGCAAGT GAGCAAGATT CTGAGATTGT

GGTTGGAAAG GAGCAAGCTC GAGCTAAAGT AACACAAAGC ATTGTCTTTG

10 TAACCGGCGA

AGCTTCTCCT TAATCGAAAG TCTGGGGGTC TAGGAGATGT TTGTGGTTCA

CTCTTGCTGC TCGCGGTCAC CGTGTGATGG TTGTAATGCC CAGACATTTA
AATGGTACCT

15 CCGATAAGAA TTATGCAAAT GCATTTTACT CAGAAAAACA CATTCGGATT CCATTCTTTG

GCGGTGAACA TGAAGTTACC TTCTTCCATG AGTATAGAGA TTCAGTTGAC TGGGTGTTTG

TTGATCATCC CTCATATCAC AGACCTGGAA ATTTATATGG AGATAAGTTT 2° GGTGCTTTTG

GTGATAATCA GTTCAGATAC ACACTCCTTT GCTATGCTGC ATGTGAGGCT CCTTTGGTCC

TTGAATTGGG AGGATATATT TATGGACAGA ATTGCATGTT GGTTGTCAAT GATTGGCATG

25 CCAGTCTAGA GCCAGTCCTT CTTGCTGCAA AATATAGACC ATATGGTGTT TATAAAGACT

CCCGCAGCAT TCTTGTAATA CATAATTTAG CACATCAGGG TGTAGAGCCT GCAAGCACAT

ATCCTGACCT TGGGTTGCCA CCTGAATGGT ATGGAGCTCT GGAGTGGGTA
30 TTCCCTGAAT

GGGCGAGGAG GCATGCCCTT GACAAGGGTG AGGCAGTTAA TTTTTTGAAA GGTGCAGTTG

TGACAGCAGA TCGAATCGTG ACTGTCAGTA AGGGTTATTC ATGGGAGGTC ACAACTGCTG

5 AAGGTGGACA GGGCCTCAAT GAGCTCTTAA GCTCCAGAAA GAGTGTATTA AACGGAATTG

TAAATGGAAT TGACATTAAT GATTGGAACC CTGCCACAGA CAAATGTATC CCCTGTCATT

ATTCTGTTGA TGACCTCTCT TGAAAGGCTA AATGTAAAGG TGCATTGCAG

10 AAGGAGCTGG

GTTTACCTAT AAGGCCTGAT GTTCCTCTGA TTGGCTTTAT TGGAAGATTG GATTATCAGA

AAGGCATTGA TCTCATTCAA CTTATCATAC CAGATCTCAT GCGGAAGAAT GTTCAA TTTG

15 TCATGCTTGG ATCTGGTGAC CCAGAGCTTG AAGATTGGAT GAGATCTACA GAGTCGATCT

TCAAGGATAA ATTTCGTGGA TGGGTTGGAT TTAGTGTTCC AGTTTCCCAC CGAATAACTG

CGGCTGGCGA TATATTGTTA ATGCCATCCA GATTCGAACC TTGTGGTCTC

ATGCTATGCA GTATGGCACA GTTCCTGTTG TCCATGCAAC TGGGGGCCTT AGAGATACCG

TGGAGAACTT CAACCCTTTC GGTGAGAATG GAGAGCAGGG TACAGGGTGG

25 CCCTAACCAC AGAAAACATG TTTGTGGACA TTGCGAACTG CAATATCTAC ATACAGGGAA

CACAAGTAAT AATGGGAAGG GCTAATGAAG CCAGGCATGT CAAAAGAGTT CACGTGGGAC

CATGCCGCTG AACAATACGA ACAAATCTTC CAGTGGGCCT TCATCGGATC
30 GACCCGATGT

TCAATGGAAA AAAGGGACCA AAGTTGGTTG GTTCCTTGAA GATTATCAGT

ATAGTAAGCT GAATGATGAA AGAAAACCCC TGTACATTAC ATGGAAGGCA GACCGGCTAT

GGAATCCAGN CGAACGACAG TTTTGAAGGA TAGGAAGGGG AGCTGGAAGC AGTCACGCAG

GCAGGCAAGC CTTCGCCGTT AATTCATATG GAACAAGCTG GAGTCAGTTT

10 CTGCTGTGCC

ACTCACTGTT TACCTTAAGA TTATTACCTG TGTTGTTCTC CTTTGCTCGT TAGGGCTGAT

AACATAATGA CTCATTAAGA ATATAATTCA CTCTGCCTCG TTTTTAATCT TAAGTGAAGT

SEQ-ID-NO2; DNA; 2085 BP.

CC NOTE: ORIGINAL SEQUENCE NAME WAS SSS CLONE 6.31

20 SQ SEQUENCE 2085 BP; 456 A; 521 C; 629 G; 479 T; 0 OTHER;

AACGCCGCAT TGGCACGTTG AGATCAAGTC CATCGTCGCC GCGCCGCCGA

GAAGTTCCCA GGGCGCGGC TACAGGATGA TCCTTCCCTC TGGGACATAG CGCCGGAGAC

25 TGTCCTCCCA GCCCCGAAGC CACTGCATGA ATCGCCTGCG GTTGACGGAG ATTCAAATGG

AATTGCACCT CCTACAGTTG AGCCATTAGT ACAGGAGGCC ACTTGGGATT TCAAGAAATA

CATCGGTTTT GACGAGCCTG ACGAAGCGAA GGATGATTCC AGGGTTGGTG CAGATGATGC

TGGTTCTTTT GAACATTATG GGACAATGAT TCTGGGCCTT TGTGGGGAGA

5 CGTGATCGTG GTGGCTGCTG AATGTTCTCC ATGGTGCAAA ACAGGTGGTC
TTGGAGATGT

TGTGGGAGCT TTACCCAAGG CTTTAGCGAG AAGAGGACAT CGTGTTATGG

AAGGTATGGG GACTATGTGG AAGCCTTTGA TATGGGAATC CGGAAATACT
10 ACAAAGCTGC

AGGACAGGAC CTAGAAGTGA ACTATTTCCA TGCATTTATT GATGGAGTCG ACTTTGTGTT

CATTGATGCC TCTTTCCGGC ACCGTCAAGA TGACATATAT GGGGGAAGTA GGCAGGAAAT

CATGAAGCGC ATGATTTTGT TTTGCAAGGT TGCTGTTGAG GTTCCTTGGC ACGTTCCATG

CGGTGGTGTG TGCTACGGAG ATGGAAATTT GGTGTTCATT GCCATGAATT GGCACACTGC

ACTCCTGCCT GTTTATCTGA AGGCATATTA CAGAGACCAT GGGTTAATGC

CTCCGTCCTC GTCATACATA ACATCGGCCA CCAGGGCCGT GGTCCTGTAC ATGAATTCCC

GTACATGGAC TTGCTGAACA CTAACCTTCA ACATTTCGAG CTGTACGATC CCGTCGGTGG

25 CGAGCACGCC AACATCTTTG CCGCGTGTGT TCTGAAGATG GCAGACCGGG
TGGTGACTGT

CAGCCGCGC TACCTGTGGG AGCTGAAGAC AGTGGAAGGC GGCTGGGGCC TCCACGACAT

CATCCGTTCT AACGACTGGA AGATCAATGG CATTCGTGAA CGCATCGACC
30 ACCAGGAGTG

- GAACCCCAAG GTGGACGTGC ACCTGCGGTC GGACGGCTAC ACCAACTACT
- ACTCGACGCT GGAAAGCGGC AGTGCAAGGC GGCCCTGCAG CGGGACGTGG
- 5 GCGCGACGAC GTGCCGCTGC TCGGCTTCAT CGGGCGTCTG GATGGACAGA AGGGCGTGGA
  - CATCATCGGG GACGCGATGC CGTGGATCGC GGGGCAGGAC GTGCAGCTGG TGATGCTGGG
- CACCGGCCCA CCTGACCTGG AACGAATGCT GCAGCACTTG GAGCGGGAGC

  10 ATCCCAACAA
  - GGTGCGCGGG TGGGTCGGGT TCTCGGTCCT AATGGTGCAT CGCATCACGC CGGGCGCCAG
  - CGTGCTGGTG ATGCCCTCCC GCTTCGCCGG CGGGCTGAAC CAGCTCTACG CGATGGCATA
- CGGCACCGTC CCTGTGGTGC ACGCCGTGGG CGGGCTCAGG GACACCGTGG CGCCGTTCGA
  - CCCGTTCGGC GACGCCGGGC TCGGGTGGAC TTTTGACCGC GCCGAGGCCA
- CGAGGTGCTC AGCCACTGCC TCGACACGTA CCGAAACTAC GAGGAGAGCT
  2 GGAAGAGTCT
  - CCAGGCGCGC GGCATGTCGC AGAACCTCAG CTGGGACCAC GCGGCTGAGC TCTACGAGGA
  - CGTCCTTGTC AAGTACCAGT GGTGAACCCT CCGCCCTCCG CATCAATATC
- TCCCATTGTA CATCGCCCTT TGACGGTCTC GGTGAAGAAC TTCATATGCA GTGCCGTGCT
  - GGGGCGGTAG CAGTACTATG GGATTGCATT GAGCTGTGTC ACTATGTGCT TTCGACAGGA
- CAGTAGTGAA GGTTCTATGC AAGTTTATTT TTTTTTCAT TACTGATATT
  30 TGGAATGTCA

### ACACAATAAA TAACTACTAT GTGTTTCGTA AGTAAAAAA AAAAA

SEQ-ID-NO3: 2478 bp DNA

04-DEC-1995

5 CC NOTE: ORIGINAL SEQUENCE NAME WAS SSS56

SUMMARY #Molecular-weight 89141 #Length 826 #Checksum 2983

BASE COUNT 347 A 276 C 533 G 290 T

ORIGIN

- I GCNGCNGCNT GGTRRGCNYT NGTNCARGCN GARGCNGCNG TNGCNTRRGG
  10 NATHCCNATG
  - 61 CCNGGNGCNA THWSNWSNWS NWSNWSNGCN TTYYTNYTNC CNGTNGCNWS NWSNWSNCCN
  - 121 MGNMGNMGNM GNGGNWSNGT NGGNGCNGCN YTNMGNWSNT AYGGNTAYWS NGGNGCNGAR
- 15 181 YTNMGNYTNC AYTGGGCNMG NMGNGGNCCN CCNCARGAYG GNGCNGCNWS NGTNMGNGCN
  - 241 GCNGCNGCNC CNGCNGGNGG NGARWSNGAR GARGCNGCNA ARWSNWSNWSNWSNWSNCAR
- 301 GCNGGNGCNG TNCARGGNWS NACNGCNAAR GCNGTNGAYW SNGCNWSNCC NCCNAAYCCN
  - 361 YTNACNWSNG CNCCNAARCA RWSNCARWSN GCNGCNATGC ARAAYGGNAC NWSNGGNGGN
  - 421 WSNWSNGCNW SNACNGCNGC NCCNGTNWSN GGNCCNAARG CNGAYCAYCC NWSNGCNCCN
- 25 481 GTNACNAARM GNGARATHGA YGCNWSNGCN GTNAARCCNG ARCCNGCNGG NGAYGAYGCN
  - 541 MGNCCNGTNG ARWSNATHGG NATHGCNGAR CCNGTNGAYG CNAARGCNGA YGCNGCNCCN

- 601 GCNACNGAYG CNGCNGCNWS NGCNCCNTAY GAYMGNGARG AYAAYGARCC NGGNCCNYTN
- 661 GCNGGNCCNA AYGTNATGAA YGTNGTNGTN GTNGCNWSNG ARTGYGCNCC NTTYTGYAAR
- 5 721 ACNGGNGGNY TNGGNGAYGT NGTNGGNGCN YTNCCNAARG CNYTNGCNMG NMGNGGNCAY
  - 781 MGNGTNATGG TNGTNATHCC NMGNTAYGGN GARTAYGCNG ARGCNMGNGA YYTNGGNGTN
- 841 MGNMGNMGNT AYAARGTNGC NGGNCARGAY WSNGARGTNA CNTAYTTYCA 10 YWSNTAYATH
  - 901 GAYGGNGTNG AYTTYGTNTT YGTNGARGCN CCNCCNTTYM GNCAYMGNCA YAAYAAYATH
  - 961 TAYGGNGGNG ARMGNYTNGA YATHYTNAAR MGNATGATHY TNTTYTGYAA RGCNGCNGTN
- 15 1021 GARGTNCCNT GGTAYGCNCC NTGYGGNGGN ACNGTNTAYG GNGAYGGNAA YYTNGTNTTY
  - 1081 ATHGCNAAYG AYTGGCAYAC NGCNYTNYTN CCNGTNTAYY TNAARGCNTA YTAYMGNGAY
- 1141 AAYGGNYTNA TGCARTAYGC NMGNWSNGTN YTNGTNATHC AYAAYATHGC
  NCAYCARGGN
  - 1201 MGNGGNCCNG TNGAYGAYTT YGTNAAYTTY GAYYTNCCNG ARCAYTAYAT HGAYCAYTTY
  - 1261 AARYTNTAYG AYAAYATHGG NGGNGAYCAY WSNAAYGTNT TYGCNGCNGG NYTNAARACN
- 25 1321 GCNGAYMGNG TNGTNACNGT NWSNAAYGGN TAYATGTGGG ARYTNAARAC NWSNGARGGN
  - 1381 GGNTGGGGNY TNCAYGAYAT HATHAAYCAR AAYGAYTGGA ARYTNCARGG NATHGTNAAY
- 1441 GGNATHGAYA TGWSNGARTG GAAYCCNGCN GTNGAYGTNC AYYTNCAYWS
  30 NGAYGAYTAY

1501 ACNAAYTAYA CNTTYGARAC NYTNGAYACN GGNAARMGNC ARTGYAARGC NGCNYTNCAR

1561 MGNCARYTNG GNYTNCARGT NMGNGAYGAY GTNCCNYTNA THGGNTTYAT HGGNMGNYTN

5 1621 GAYCAYCARA ARGGNGTNGA YATHATHGCN GAYGCNATHC AYTGGATHGC NGGNCARGAY

1681 GTNCARYTNG TNATGYTNGG NACNGGNMGN GCNGAYYTNG ARGAYATGYT NMGNMGNTTY

1741 GARWSNGARC AYWSNGAYAA RGTNMGNGCN TGGGTNGGNT
10 TYWSNGTNCC NYTNGCNCAY

1801 MGNATHACNG CNGGNGCNGA YATHYTNYTN ATGCCNWSNM GNTTYGARCC NTGYGGNYTN

1861 AAYCARYTNT AYGCNATGGC NTAYGGNACN GTNCCNGTNG TNCAYGCNGT NGGNGGNYTN

15 1921 MGNGAYACNG TNGCNCCNTT YGAYCCNTTY AAYGAYACNG GNYTNGGNTG GACNTTYGAY

1981 MGNGCNGARG CNAAYMGNAT GATHGAYGCN YTNWSNCAYT GYYTNACNAC NTAYMGNAAY

2041 TAYAARGARW SNTGGMGNGC NTGYMGNGCN MGNGGNATGG 2° CNGARGAYYT NWSNTGGGAY

2101 CAYGCNGCNG TNYTNTAYGA RGAYGTNYTN GTNAARGCNA ARTAYCARTG GTRRGCNAAY

2161 TRRYTNGCNA CNMGNMGNMG NWSNTGYMGN MGNACNTGGA CNYTNTTYMG NMGNYTNTTY

25 2221 WSNYTNGCNG CNYTNATGMG NGCNWSNCAY YTNMGNMGNG CNGAYGGNMG NMGNTGGYTN

2281 GCNTAYMGNY TNMGNMGNYT NMGNGCNYTN GGNATHTGGG CNGGNACNAT GATGCCNYTN

2341 GGNACNGGNM GNGGNGTNGT NTRRTAYGAR ACNGAYGGNG 30 AYGGNGAYGA RGCNCAYGGN 2401 ATHTTYCCNY TNATHAAYGG NGARYTNTAY GCNACNYTNA THWSNCCNYT NYTNYTNGTN

2461 TTYATHYTNA TGGCNGCN

10

15

20

25

30


#### **CLAIMS**

- A cDNA specifying a soluble starch synthase having the sequences of the
  inserts in plasmids pSSS6, pSSS10.1 and pSSS6.31 and sequences having
  sufficient similarity such that when inserted into the genome of an organism
  which produces starch, the synthesis of starch is altered.
- The cDNA of the insert of plasmid pSSS6, deposited under the terms of the Budapest Treaty, with the National Collections of Industrial and Marine Bacteria Limited, 23 St Machar Drive, Aberdeen AB1 2RY, on 13th June 1994, under the Accession Number 40651.
  - 3. The cDNA of the insert in plasmid pSSS6.31, deposited under the terms of the Budapest Treaty, with the National Collections of Industrial and Marine Bacteria Limited, 23 St Machar Drive, Aberdeen AB1 2RY, on 22nd August 1994, under the Accession Number NCIMB 40679.
- 4. The cDNA of the insert in plasmid pSSS10.1, deposited under the terms of the Budapest Treaty, with the National Collections of Industrial and Marine Bacteria Limited, 23 St Machar Drive, Aberdeen AB1 2RY, on 22nd August 1994, under the Accession Number NCIMB 40680.
  - A cDNA, encoding soluble starch synthase which has the sequence SEQ-ID-NO-1, or SEQ-ID-NO-2 or SEQ-ID-NO-3.
  - 6. A transformed plant containing one or more copies of one or more of the said cDNAs claimed in claim 5 in sense or antisense orientation.
  - A method of producing a plant with altered starch synthesising ability comprising stably incorporating into the genome of a recipient plant one or

more than one donor gene specifying soluble starch synthase as claimed in claim 5.


- A method as claimed in claim 7 in which the recipient plant is of the family 8. Gramineae.
- A method as claimed in claim 8 in which the recipient plant is of the species 9. Zea mays.
- Seeds of a plant as claimed in claim 6. 10 10.

# FIGURE 1



SUBSTITUTE SHEET (RULE 26)

### FIGURE 2



SUBSTITUTE SHEET (RULE 26)

# INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism re- on page FIVE time 16	rerred to in the description - 23 inclusive
B. IDENTIFICATION OF DEPOSIT	Further deposits are identified on an additional sheet
Name of depositary institution	
NCIMB	
Address of depositary institution (including postal code and country	,
23 St Machar Drive, Aberdeen AB	1 2RY
Date of deposit 13.06.94 22.08.94	Accession Number 40651 40679
22_08_94	40680
C. ADDITIONAL INDICATIONS (leave blank if not applicable	(k) This information is continued on an additional sheet
	·
D. DESIGNATED STATES FOR WHICH INDICATION	ONS ARE MADE (if the indications are not for all designated States)
. •	
	·
E. SEPARATE FURNISHING OF INDICATIONS (leave	Bureau later (specify the general nature of the indications e.g., "Accession
Number of Deposit')	rates are specifical formation
	1
·	
For receiving Office use only	For International Bureau use only
This sheet was received with the international application	This sheet was received by the International Bureau on:
Authorized officer	Authorized officer

Form PCT/RO/134 (July 1992)

# BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANIEWS FOR THE PURPOSES OF PATENT PROCEDURE

Zeneca Seeds, Vealotts Hill Research Station, Bracknell, Berkshire.

RC12 GEY

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED DEFINANT TO RULE 7.1 by the INTERNATIONAL DEPOSITARY AUTHORITY Identified at the bottom of this page

NAME AND ADDRESS OF DEPOSITOR

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR:	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:
Escherichia coli Sol R containing plasmid pSSS6.31	NCIMB 40679
11. SCIENTIFIC DESCRIPTION AND/OR PROPOSED	TAXONOMIC DESIGNATION
The microorganism identified under I above	vas accompanied by:
a scientific description	
X a proposed taxonomic designation	
(Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accumulation was received by it on 22 August 1994 do	epts the microorganism identified under I above, ate of the original deposit).
IV. RECEIPT OF REQUEST FOR CONVERSION	
a request to convert the original deposit to	te of the original deposit) and
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Difference of the California of the Califo	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: 23 August 1994

form BP/4 (sole page)

Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.

IV. CONDITIONS UNDER WHICH THE VIABILITY TEST H	AS BEEN PERFORMED 4
·	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Address: 23 St Machar Drive Abordeen Scotland	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Depos: 23 August 1994

Form BP/9 (second and last page)

 $\pm j$ 

<sup>&</sup>lt;sup>4</sup> Fill in if the information has been requested and if the results of the test were negative.

#### BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANIS FOR THE PURPOSES OF PATENT PROCEDURE

### INTERNATIONAL FORM .

TO RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT  issued pursuant to Rule 7.1 by the  INTERNATIONAL DEPOSITARY AUTHORITY  identified at the bottom of this page  Station,  Bracknell, Berkshire, RG12 6EY
NAME AND ADDRESS OF DEPOSITOR
1. IDENTIFICATION OF THE NICEOORGANISM
Identification reference given by the Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:
Escherichia coli Sol R containing plasmid pSSS10.1 NCIMB 40680
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION
The microorganism identified under I above was accompanied by:
a scientific description
X a proposed taxonomic designation
(Mark with a cross where applicable)
III. RECEIFT AND ACCEPTANCE
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on 22 August 1994(date of the original deposit).
IV. RECEIPT OF REQUEST FOR CONVERSION
The microorganism identified under I above was received by this International Depositary Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)
V. INTERNATIONAL DEPOSITARY AUTHORITY
Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorised official(s):  Address: USC Date: 23 August 1994

Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.

Porm BP/4 (sole page)

į.

# JUAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF HICROORGANISMS FOR THE PURPOSES OF PATERY PROCEDURE

Zeneca Seeds, Jealotts Hill Research Station, Bracknell, Berkshire. RG12 6EY THERMATIONAL FUND

VIANUALTY STATEMENT Langed pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY Identified on the following page

HART AND ADDRESS OF THE PARTY TO WHOM THE VIABILITY STATEMENT IS ISSUED

1. DEPOSITOR	11. IUSHTIFICATION OF THE HICROGRAMISH
Addrese: AS ABOVE	Account number given by the international Derusitant AUTHORITY:  NCIMB 40680 Date of the deposit or of the transfers
·	22 August 1994
III. VIABILITY STATEMENT	
The viability of the microorganism identified un on 22 August 1994	der II above was tested  2. On that date, the said microorganism was
X viable	, in the second
no longer viable	

Form BP/9 (first page)

Indicate the date of the original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).

In the cases referred to in Rule 10.2(a)(ii) and (iii), refer to the most recent viability toot.

Hark with a cross the applicable box.

ıv.	CONDITIONS	UNDER WHICH	THE VIABILITY	TEST HAS BEEN PERFORMED 4
	•			
		•		
v.	INTERNATION	ial depositat	TY AUTHORITY	
Name	خاندر	ottess nee	bred?	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):
Addr		mil section 1		Date: 23 August 1994

<sup>4</sup> Fill in if the information has been requested and if the results of the test were negative.

# DUMPRESS GREATS ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF PATENT PROCEDURE

Zeneca Limited Zeneca Seeds Jealott's Hill Research Station Bracknell Berkshire RG12 6EY

## INTERNATIONAL FORM

RECRIPT IN THE CASE OF AN ORIGINAL DEPOSITION OF THE PROPERTY OF THE PROPERTY AND PROPERTY IDENTIFY ALTERNATION AT THE BOLLOW OF THIS page.

MAJIE AND ADDRESS OF DEPOSITOR

I. IDENTIFICATION OF THE MICROORGANISM
Identification reference given by the Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:
Escherichia coli Sol R containing plasmid pSSS6 NCIMB 40651
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONHMIC DESIGNATION
The microorganism identified under I above was accompanied by:
a scientific description
A proposed taxonomic designation
(Mark with a cross where applicable)
111. RECEIPT AND ACCEPTANCE
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on 13 June 1994 (date of the original deposit).
TV. RECEIPT OF REQUEST FOR CONVERSION
The microorganism identified under I above was received by this international Depositary Authority on (date of the original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion)
V. INTERNATIONAL DEPOSITARY AUTHORITY
Hame:  23 St. dia  Absideon  Address: IIK A''  Date:  June 1994

Where Rule 6.4(d) applies, such date is the date on which the status of international depositary authority was acquired.

toth BP/4 (sole page)

# UDAPEST TREATY ON THE LITERMATIONAL RECOGNITION OF THE DEPOSIT OF MICROORGANISHS FOR THE PURPOSES OF FATERY PROCEDURE

INTERNATIONAL FORM

Zeneca Limited

Zeneca Seeds
Jealott's Hill Research Station
Bracknell
Berkshire

VIABILITY STATEMENT Innerd pursuant to Rule 10.2 by the INTERNATIONAL DEPOSITARY AUTHORITY Identified on the following page

HAVIS AND ADDRESS OF THE PARTY TO WHOM THE VIADILITY STATEMENT 18 ISSUED

RG12 6EY

1. DEPOSITOR	11. IDENTIFICATION OF THE DICHORDANISH
Homo: As above	Administrational Defositant Authority:  NCIMB 40651  Date of the deposit or of the transfers
	13 June 1994
III. VIABILITY STATEMENT	
The viability of the microoxyanis	m identified under II above was tested
on 13 June 1994	<ol> <li>On that date, the said microorganism was:</li> </ol>
X viable	
no longer viable	

Indicate the date of the original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).

Form BP/9 (first page)

In the cases referred to in Num 10.2(a)(ii) and (iii), refer to the most recent viability toot.

Hark with a cross the applicable box.

IV.	CONDITIONS UNDER WHICH THE VIABILITY TEST H	as been performed 4
	·	-
	gen Company	
		÷
	•	
٠v.	INTERNATIONAL DEPOSITARY AUTHORITY	
Nam	reset 23 St sharper Apardican	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):  Date: 14 June 1994

A Professor Sendar Pale

Fill in if the information has been requested and if the results of the test were negative.

# INTERNATIONAL SEARCH REPORT

PCT/GB 96/02990

IPC 6	FICATION OF SUBJECT MATTER C12N15/52 C12N15/82 A01H5/0		
According to	o International Patent Classification (IPC) or to both national class	nitration and IPC	
B. FIELDS	SEARCHED		
Minimum d IPC 6	ocumentation searched (classification system followed by classification (C12N A01H	ation symbols)	· · · · · · · · · · · · · · · · · · ·
Documental	non searched other than minimum documentation to the extent that	t such documents are included in the helds s	earched
Electronic d	lata base consulted during the international search (name of data bi	ase and, where practical, search terms used)	
C. DOCUM	IENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the	relevant passages	Relevant to claim No.
X	PLANT PHYSIOL., vol. 108, no. 2 June 1995, page 50, abstract no. C. HARN ET AL.: "Isolation of a synthase cDNA clone from maize W XP000651998 see the abstract. & 1995 annual meeting of the Ame Plant Physiol., Charlotte, N. USA, July 29th - August 2nd, 1	187, starch 64A" er. Soc. of Carolina,	1-10
х	WO 94 09144 A (ZENECA LTD.) 28 A see pages 39-41, Example 4 and C		1-10
X Furt	her documents are listed in the continuation of box C.	X Patent family members are listed :	n annex.
"A" docum consid "E" earlier filing o "L" docum which crasho "O" docum other o	ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another in or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or	"T" later document published after the inter- or priority date and not in conflict we cited to understand the principle or the invention.  "X" document of particular relevance; the cannot be considered novel or cannot involve an inventive ttep when the do- "Y" document of particular relevance; the cannot be considered to involve an in- document is combined with one or in- ments, such combined with one or in- the art.  "A" document member of the same patent	th the application but seery underlying the claimed invention he considered to current is taken alone claimed invention ventive step when the one other such docu- is to a person dulled
	actual completion of the international search 7 April 1997	Date of mailing of the international se	arch report
Name and r	mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rigswyk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fair (-51:70) 340-3016	Authorized officer Yeats, S	!

1.

# INTERNATIONAL SEARCH REPORT

Internation pplication No PCT/GB 96/02990

ategory *	Citation of document, with indication, where appropriate, of the relevant passages	
	commend and information also abbrobines of me income being for	Relevant to claim No.
Κ	PLANT J.,	1-10
	vol. 6, no. 2, 1994,	1
	pages 151-159, XP000651922	1
	C. MU ET AL.: "Association of a 76 kDa polypeptide with soluble starch synthase I	i i
	activity in maize (cv B73) endosperm*	
	see the whole document, in particular the	,
	summary, Table 1 and the last paragraph	
-	of the discussion.	į.
J	NAME OF THE OWNER OWN	
Х	PLANT PHYSIOL., vol. 103, 1993,	1,6,7,10
	pages 565-573, XP000565731	
	T. BABA ET AL.: "Identification, cDNA	
	cloning, and gene expression of soluble	<u> </u>
	starch synthase in rice (Oryza sativa L.)	•
·	immature seeds"	
	cited in the application	
	see the abstract and Figure 5.	
x	J. BIOL. CHEM.,	1
	vol. 260, 1985,	
	pages 16451-16459, XP000652758	
	M.D. MARKS ET AL.: "Nucleotide sequence	
	analysis of zein mRNAs from maize	
	endosperm" see abstract and Figure 4, clone cZ19Cl.	
A	EP 0 521 621 A (ADVANCED TECHNOLOGIES (CAMBRIDGE) LTD.) 7 January 1993 see the claims.	1,6,7
	(CAMBRIDGE) LTD.) 7 January 1993 see the claims.	
	(CAMBRIDGE) LTD.) 7 January 1993	1,6,7
	(CAMBRIDGE) LTD.) 7 January 1993 see the claims. WO 96 15248 A (INSTITUT FÜR GENBIOLOGISCHE FORSCHUNG BERLIN GMBH) 23 May 1996	
	(CAMBRIDGE) LTD.) 7 January 1993 see the claims. WO 96 15248 A (INSTITUT FÜR GENBIOLOGISCHE FORSCHUNG BERLIN GMBH) 23 May 1996	
A P,X	(CAMBRIDGE) LTD.) 7 January 1993 see the claims. WO 96 15248 A (INSTITUT FÜR GENBIOLOGISCHE FORSCHUNG BERLIN GMBH) 23 May 1996	
	(CAMBRIDGE) LTD.) 7 January 1993 see the claims.  WO 96 15248 A (INSTITUT FÜR GENBIOLOGISCHE FORSCHUNG BERLIN GMBH) 23 May 1996 see Examples 1-12 and Claims.	
	(CAMBRIDGE) LTD.) 7 January 1993 see the claims.  WO 96 15248 A (INSTITUT FÜR GENBIOLOGISCHE FORSCHUNG BERLIN GMBH) 23 May 1996 see Examples 1-12 and Claims.	
	(CAMBRIDGE) LTD.) 7 January 1993 see the claims.  WO 96 15248 A (INSTITUT FÜR GENBIOLOGISCHE FORSCHUNG BERLIN GMBH) 23 May 1996 see Examples 1-12 and Claims.	
	(CAMBRIDGE) LTD.) 7 January 1993 see the claims.  WO 96 15248 A (INSTITUT FÜR GENBIOLOGISCHE FORSCHUNG BERLIN GMBH) 23 May 1996 see Examples 1-12 and Claims.	
	(CAMBRIDGE) LTD.) 7 January 1993 see the claims.  WO 96 15248 A (INSTITUT FÜR GENBIOLOGISCHE FORSCHUNG BERLIN GMBH) 23 May 1996 see Examples 1-12 and Claims.	
	(CAMBRIDGE) LTD.) 7 January 1993 see the claims.  WO 96 15248 A (INSTITUT FÜR GENBIOLOGISCHE FORSCHUNG BERLIN GMBH) 23 May 1996 see Examples 1-12 and Claims.	
	(CAMBRIDGE) LTD.) 7 January 1993 see the claims.  WO 96 15248 A (INSTITUT FÜR GENBIOLOGISCHE FORSCHUNG BERLIN GMBH) 23 May 1996 see Examples 1-12 and Claims.	
	(CAMBRIDGE) LTD.) 7 January 1993 see the claims.  WO 96 15248 A (INSTITUT FÜR GENBIOLOGISCHE FORSCHUNG BERLIN GMBH) 23 May 1996 see Examples 1-12 and Claims.	
	(CAMBRIDGE) LTD.) 7 January 1993 see the claims.  WO 96 15248 A (INSTITUT FÜR GENBIOLOGISCHE FORSCHUNG BERLIN GMBH) 23 May 1996 see Examples 1-12 and Claims.	
	(CAMBRIDGE) LTD.) 7 January 1993 see the claims.  WO 96 15248 A (INSTITUT FÜR GENBIOLOGISCHE FORSCHUNG BERLIN GMBH) 23 May 1996 see Examples 1-12 and Claims.	
	(CAMBRIDGE) LTD.) 7 January 1993 see the claims.  WO 96 15248 A (INSTITUT FÜR GENBIOLOGISCHE FORSCHUNG BERLIN GMBH) 23 May 1996 see Examples 1-12 and Claims.	
	(CAMBRIDGE) LTD.) 7 January 1993 see the claims.  WO 96 15248 A (INSTITUT FÜR GENBIOLOGISCHE FORSCHUNG BERLIN GMBH) 23 May 1996 see Examples 1-12 and Claims.	
	(CAMBRIDGE) LTD.) 7 January 1993 see the claims.  WO 96 15248 A (INSTITUT FÜR GENBIOLOGISCHE FORSCHUNG BERLIN GMBH) 23 May 1996 see Examples 1-12 and Claims.	
	(CAMBRIDGE) LTD.) 7 January 1993 see the claims.  WO 96 15248 A (INSTITUT FÜR GENBIOLOGISCHE FORSCHUNG BERLIN GMBH) 23 May 1996 see Examples 1-12 and Claims.	

Form PCT ISA 218 (continuous of second sheet) (July 1992

page 2 of 2

### INTERNATIONAL SEARCH REPORT

Information on patent family members

PCT/GB 96/02990

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9409144 A	28-04-94	AU 2696492 A EP 0664835 A	09-05-94 02-08-95
EP. 521621 A	07-01-93	CA 2071010 A US 5365016 A	13-12-92 15-11-94
WO 9615248 A	23-05-96	DE 4441408 A - AU 3927995 A	15-05-96 06-06-96

Form PCT.(SA 216 (palent family annex) (July 1992)

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

# **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:
BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
☐ LINES OR MARKS ON ORIGINAL DOCUMENT
REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
OTHER:

# IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

# RIANK PAGE